Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Akero Therapeutics Inc shares valued at $201,258 were sold by Lamy Patrick on Jun 02 ’25. At $50.31 per share, Lamy Patrick sold 4,000 shares. The insider’s holdings dropped to 33,492 shares worth approximately $1.81 million following the completion of this transaction.
Also, Lamy Patrick sold 4,000 shares, netting a total of over 200,000 in proceeds. Following the sale of shares at $50.00 each, the insider now holds 33,492 shares.
Before that, PATRICK D LAMY had added 10,000 shares to its account. In a trade valued at $483,500, the Officer bought Akero Therapeutics Inc shares for $48.35 each.
As published in a research note from BofA Securities on January 30, 2025, Akero Therapeutics Inc [AKRO] has been rated up from a Neutral to a Buy and the price target has been revised to $63 from $35. Analysts at H.C. Wainwright resumed the stock at ‘”a Buy”‘ outlook in a report released in late January. As of November 18, 2024, Citigroup has initiated its “Buy” rating for AKRO.
Analyzing AKRO Stock Performance
During the last five days, there has been a surge of approximately 12.30%. Over the course of the year, Akero Therapeutics Inc shares have jumped approximately 93.89%. Shares of the company reached a 52-week high of $58.40 on 01/27/25 and a 52-week low of $21.34 on 01/14/25.
Support And Resistance Levels for Akero Therapeutics Inc (AKRO)
According to the 24-hour chart, there is a support level at 52.66, which, if violated, would cause prices to drop to 51.37. In the upper region, resistance lies at 54.72. The next price resistance is at 55.49. RSI (Relative Strength Index) is 69.93 on the 14-day chart, showing neutral technical sentiment.
